Wells Fargo & Company Evelo Biosciences, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.17 - $1.57 $2 - $18	12 Added 3.08%	402 $0
Q4 2022 Feb 13, 2023	BUY	$1.44 - $48.2 $14 - $482	10 Added 2.63%	390 $0
Q3 2022 Nov 14, 2022	BUY	$1.86 - $41.8 $366 - $8,234	197 Added 107.65%	380 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.46 - $3.55 $2,411 - $5,864	-1,652 Reduced 90.03%	183 $0
Q1 2022 May 16, 2022	SELL	$2.66 - $6.63 $28,823 - $71,842	-10,836 Reduced 85.52%	1,835 $6,000
Q4 2021 Feb 14, 2022	BUY	$6.07 - $12.0 $76,688 - $151,608	12,634 Added 34145.95%	12,671 $76,000
Q2 2021 Aug 16, 2021	SELL	$9.43 - $16.6 $471,754 - $830,448	-50,027 Reduced 99.93%	37 $1,000
Q1 2021 May 13, 2021	BUY	$9.71 - $18.6 $77,612 - $148,669	7,993 Added 19.0%	50,064 $535,000
Q4 2020 Feb 09, 2021	BUY	$3.91 - $12.28 $21,884 - $68,731	5,597 Added 15.35%	42,071 $508,000
Q3 2020 Nov 05, 2020	SELL	$3.81 - $5.73 $758 - $1,140	-199 Reduced 0.54%	36,474 $192,000
Q2 2020 Aug 13, 2020	BUY	$3.53 - $6.12 $90,837 - $157,485	25,733 Added 235.22%	36,673 $180,000
Q1 2020 May 14, 2020	BUY	$3.21 - $7.06 $35,117 - $77,236	10,940 New	10,940 $41,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.